SCHEMBL27233451

SCHEMBL27233451

CCOC(=O)COc1ccc(SCn2ncn(-c3ccc(Br)cc3)c2=O)cc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 11/20 0.47
PPARA Q07869 8/20 0.47
PPARG P37231 6/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.41
POLB P06746 3/20 0.41
PABPC1 P11940 1/20 0.41
APOBEC3A P31941 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
ESR1 P03372 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPK1 P28482 1/20 0.38
ALDH1A1 P00352 4/20 0.37
HPGD P15428 3/20 0.37
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HTT P42858 1/20 0.37
CASP6 P55212 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27233506 0.93 PPARD (0.43) PPARDPPARAPPARGPTGDR2POLB
SCHEMBL27233381 0.91 ALDH1A1 (0.42) PPARDPPARAPPARGPTGDR2POLB
SCHEMBL27233348 0.91 PPARD (0.43) PPARDPPARAPPARGPTGDR2POLB
SCHEMBL27233400 0.91 PPARD (0.49) PPARDPPARAPPARGPOLBESR1
SCHEMBL27233332 0.91 PPARD (0.47) PPARDPPARAPPARGESR1
SCHEMBL27233441 0.91 PPARD (0.49) PPARDPPARAPPARGESR1KDM4E
SCHEMBL27233431 0.91 PPARD (0.47) PPARDPPARAPPARGESR1MEN1
SCHEMBL27233516 0.90 PPARD (0.53) PPARDPPARAPPARGPTGDR2
SCHEMBL27233336 0.89 PPARD (0.47) PPARDPPARAPPARGPTGDR2POLB
SCHEMBL27233333 0.89 PPARD (0.60) PPARDPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188044-A1 TRIAZOLONE COMPOUND, PHARMACEUTICAL USE THEREOF AND PHARMACEUTICAL COMPOSITION HARBIN MEDISAN PHARMACEUTICAL CO., LTD. (CN) 2025-06-12 US claimed
EP-4378931-A1 TRIAZOLONE COMPOUND AND MEDICINAL USE THEREOF Harbin Medisan Pharmaceutical Co., LTD. (CN) 2024-06-05 EP claimed
US-20250188044-A1 TRIAZOLONE COMPOUND, PHARMACEUTICAL USE THEREOF AND PHARMACEUTICAL COMPOSITION HARBIN MEDISAN PHARMACEUTICAL CO., LTD. (CN) 2025-06-12 US disclosed
EP-4378931-A1 TRIAZOLONE COMPOUND AND MEDICINAL USE THEREOF Harbin Medisan Pharmaceutical Co., LTD. (CN) 2024-06-05 EP disclosed
CN-114853686-B Triazolone compound and medical application thereof 中国药科大学 2023-06-20 CN disclosed
CN-114853686-A Triazole ketone compound and medical application thereof 中国药科大学 2022-08-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188044-A1 TRIAZOLONE COMPOUND, PHARMACEUTICAL USE THEREOF AND PHARMACEUTICAL COMPOSITION PPARD, PPARA, PPARG PPARD 1/4885PPARA 2/4885PPARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.